DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Michel de Rosen has been appointed to the Company's Board of Directors, in replacement of George Horner III. Michel de Rosen's appointment will be proposed at the Company's Ordinary and Extraordinary General Meeting on June 22, 2018, in Montrouge, France. With this addition, DBV's Board now comprises eight directors.

Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV Technologies, said: "It is with great pleasure that we welcome Michel to DBV. We believe his extensive business experience in the biopharmaceutical industry, with 15 years spent in the US, will continue strengthening our team, and that his advice will be instrumental as we move closer to bringing potential treatments to patients suffering from peanut allergy and other diseases."

Michel de Rosen is currently Chairman of the Board of Faurecia, a global supplier of automotive equipment and Chairman of the Board of Pharnext, a publicly-traded innovative pharmaceutical company. Previously, he served as Chairman and Chief Executive Officer of Eutelsat, Chairman and Chief Executive Officer of ViroPharma and Chairman and Chief Executive Officer of Rhône-Poulenc Santé. Earlier in his career, Michel de Rosen held key positions at the French Ministries of Finance, Defense, Industry, and Telecommunications.

"I am thrilled to join the Board of DBV at this crucial time for the Company and look forward to working closely with the Board and management team," said Michel de Rosen. "I am excited to contribute to the progress of this innovative company, notably in light of the potential approval and subsequent launch of Viaskin Peanut, its first product candidate."

About DBV Technologies 

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. The Company's ordinary shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com

DBV Media Contact
Raul Damas
Partner, Brunswick Group
+1-212-333-3810
DBV@brunswickgroup.com